Filter posts

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the …

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical ...

In his State of the Union address, President Trump called on Congress to “do more” …

Market Outlook—Leveraging Market Corrections for M&A or IPOs

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year …

New BIO Report on Impact of Sarbanes-Oxley 404(b) on Emerging Biotech Innovators

BIO is out with a new report illustrating the negative impact of Sarbanes-Oxley 404(b) on …

Health Care in Focus as President Trump Addresses the Nation

In his State of the Union address, President Trump described the need to rein in …

Here’s What You Need to Know as Capitol Hill Talks Prescription Drug Costs

Drug prices will be in the spotlight this week as committees in both the House …

Greenwood Shines Spotlight on Insurance Industry Rip-off

Writing for The Hill, BIO’s President and CEO Jim Greenwood shined a spotlight on a …

Despite Administration’s “Sky-High Rhetoric,” Importing Foreign Price Controls Will Harm Innov...

In October of 2018, the Trump Administration outlined a proposal that would import foreign price …

The Right Way to Address Prescription Drug Costs

Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City …

BIO Illustrates the Success of the Orphan Drug Act

The numbers might surprise you. Approximately 7,000 rare diseases are known to exist, and approximately …